Literature DB >> 31805464

Factor XIII activity in patients requiring surgical re-exploration for bleeding after elective cardiac surgery - A prospective case control study.

Elisabeth H Adam1, Jens Meier2, Bernd Klee3, Kai Zacharowski4, Patrick Meybohm5, Christian F Weber6, Andreas Pape7.   

Abstract

PURPOSE: Surgical re-exploration due to postoperative bleeding is associated with increased morbidity and mortality. The aim of our study was to assess a potential association between the level of postoperative FXIII activity and need for re-exploration due to bleeding in patients undergoing cardiothoracic surgery.
MATERIALS AND METHODS: In our prospective single center observational cohort study, we enrolled patients who underwent elective cardiothoracic surgery. Patients who required re-exploration (RE group) were matched to patients from the study population (non-RE group).
RESULTS: The study included 64 patients, out of a cohort of 678 patients, of whom 32 required surgical re-exploration due to bleeding within the first 24 h. Between patients of the RE and non-RE group, a significantly reduced FXIII activity was observed postoperatively (59.0 vs 71.1; p = .014). Multivariable analysis revealed reduced FXIII activity (p = .048) as a parameter independently associated with surgical re-exploration. Further, reduced FXIII activity (p = .037) and surgical re-exploration (p = .01) were significantly associated with increased 30 day mortality. In multivariable analysis re-exploration was independently associated with increased risk of 30 day mortality (p = .004, HR 9.68).
CONCLUSIONS: Reduced postoperative FXIII activity may be associated with the need for surgical re-exploration. Postoperative assessment of FXIII activity should therefore be considered in patients undergoing elective cardiothoracic surgery.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bleeding; Cardiothoracic surgery; Coagulation; Factor XIII; Surgical re-exploration

Mesh:

Substances:

Year:  2019        PMID: 31805464     DOI: 10.1016/j.jcrc.2019.11.012

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  3 in total

1.  Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity.

Authors:  Martina Leitner; Christian Büchold; Ralf Pasternack; Nikolaus B Binder; Gary W Moore
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

2.  Mild Acquired Factor XIII Deficiency and Clinical Relevance at the ICU-A Retrospective Analysis.

Authors:  Felix Carl Fabian Schmitt; Maik von der Forst; Wolfgang Miesbach; Sebastian Casu; Markus Alexander Weigand; Sonja Alesci
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

Review 3.  The impact of acquired coagulation factor XIII deficiency in traumatic bleeding and wound healing.

Authors:  Christian Kleber; Armin Sablotzki; Sebastian Casu; Martin Olivieri; Kai-Martin Thoms; Johannes Horter; Felix C F Schmitt; Ingvild Birschmann; Dietmar Fries; Marc Maegele; Herbert Schöchl; Michaela Wilhelmi
Journal:  Crit Care       Date:  2022-03-24       Impact factor: 19.334

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.